Unum Shorts Rebuild at a One-Year High as Q3 Results Loom

UNM has lost 2.1% this week, slightly more than the median decline of around 1.4% for its closest insurance peers, and the shares have now shed 3.3% over the past month. That modest underperformance comes at the same time short interest has climbed to its highest level in at least a year.

Short positions have risen roughly 4.7% over the past month to 4.5 million shares, or 2.7% of the free float, the peak reading in the data. The week-on-week change was a modest 1.4%, so this is a slow rebuild rather than a sudden rush, but the direction is consistent. What makes it an odd combination is that the borrow market is entirely relaxed. Availability is effectively unconstrained, shares available to borrow number well above 126 million against short interest of 4.5 million, and the cost to borrow, at 0.48%, is cheap despite a 36% jump on the week. There is no squeeze dynamic here. Shorts are adding positions in a liquid, low-friction market. The ORTEX short score of 33.6 sits in the 54th percentile for its sector, unremarkable on its own but trending modestly higher across each of the past four sessions. Options positioning is also calm: the put/call ratio of 0.063 is barely above its 20-day average of 0.061 and remains well below any level that would signal genuine hedging pressure.

The Street is broadly positive but has been trimming expectations. Wells Fargo raised its target to $102 earlier this month while keeping an Overweight rating, and Barclays, also Overweight, nudged its target down to $109 from $110. The cluster of targets from active analysts, spanning roughly $92 to $123, implies meaningful upside from the current $90.28, but Morgan Stanley's $92 Equal-Weight target is now barely above where the stock trades. Forward earnings estimates are moving the right way on a 12-month basis, with that factor ranking in the 78th percentile, yet near-term EPS momentum is weak, ranked 42nd over 30 days and 21st over 90 days. The bear case rests on higher group disability benefit ratios running at 62% to 63% and long-term care incidence rates that carry residual uncertainty. The bull case points to mid-single-digit premium growth, over 20% return on equity from the group benefits franchise, and free cash flow conversion above 90%. At a trailing P/E of around 10.1x and price-to-book of 1.26x, the valuation reflects more of the bear case than the bull.

Insider activity adds a mild caution signal. Open-market sales in the 90 days to September 10 total roughly $988,000 net, led by a director's $404,000 sale and the General Counsel's $378,000 sale. None were under 10b5-1 plans, which makes them discretionary rather than mechanical. No open-market purchases appear in the period. At these price levels these are small transactions relative to the company's $14.3 billion market cap, but the absence of any buying from insiders as the stock drifts lower is worth noting. On the institutional side, BlackRock has increased its stake to 11.4% of shares, while Norges Bank and Vanguard both trimmed positions in their most recently reported quarters. No 13D activist is on the register.

Wikipedia attention for UNM has risen sharply, with a retail attention z-score of 2.75 against its own 90-day history. That is a meaningful pickup in general interest, and it coincides with the stock's recent price weakness. The alt data layer carries no measured leading dataset that connects this directly to financial results, so it is colour rather than signal, but a spike in retail attention ahead of an earnings date can sometimes reflect broader news flow not yet captured in the short interest data.

Q3 results are due on 3 November. Looking back at the three most recent prints, UNM fell 3.2% and 1.3% on the two July 2026 reporting dates, though in both cases the stock recovered over the following five days. The May 2026 report produced a small positive reaction of 0.8% on the day. The pattern is a slight negative initial reaction followed by a five-day reversal, which fits with a stock where the initial read on benefit ratios often overshoots. The $92 Morgan Stanley target, currently just above the spot price, and the trajectory of disability benefit ratio assumptions are the two specific levels worth tracking into that release.